LEARNING OBJECTIVES:
At the end of this symposium, participants will be able to:

• Describe the advantages and limitations of various treatment strategies for uveitis, including local and systemic therapies, and choose the most appropriate line of therapy for different uveitis presentations
• Indicate the advantages and limitations of anti-VEGF agents in treating intraocular neovascularisation or macular edema secondary to uveitis vs. other vasculopathic causes of these conditions
• Identify patients for whom topical and periocular corticosteroids are likely to be effective and timely vs. patients with uveitis who warrant oral corticosteroid or systemic immunomodulatory treatment
• Evaluate when implants or systemic therapy is the preferred option
• Define the indications and develop a treatment plan for systemic immunosuppression in uveitis
• Describe a novel model of collaborative care between ophthalmology and rheumatology and the benefits for patients with uveitis
  

CANMEDS ROLES: Collaborator, Medical Expert

SCIENTIFIC PLANNING COMMITTEE
Eric Fortin, MD, Chair
Jean Deschênes, MD, COS Representative
Alex de Saint Sardos, MD

This symposium has been co-developed by the Canadian Ophthalmological Society (COS), the Canadian Retina Society (CRS), and the Canadian Uveitis Society (CUS) and Abbvie to achieve scientific integrity, balance and objectivity.